The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Subscribe To Our Newsletter & Stay Updated
